4 years ago

Amphista Therapeutics Secures $53 Million in Series B Funding to Advance Targeted Protein Degradation Platform

  • Amphista Therapeutics, a UK-based leader in targeted protein degradation (TPD) approaches, has secured $53 million in Series B funding

  • The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, Eli Lilly and Company, BioMotiv, and Advent Life Sciences

  • Amphista intends to use the funds to accelerate its pipeline of TPD-based medicines to the clinic and expand its platform, targeting challenging diseases like cancer

  • The company's innovative approach involves harnessing the body's natural processes to selectively remove disease-causing proteins.

    • ProblemHealthcare

      "Developing new cancer treatments is often hampered by the lack of effective and safe drugs that can target specific proteins involved in disease development."

      Solution

      "Amphista Therapeutics is developing a new type of medicine called 'Amphistas' which use the body's natural processes to selectively degrade and remove disease-causing proteins. This approach could lead to more effective and safer cancer treatments."

      Covered on